|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Serologicals Corporation (SERO) Announces Collaboration With CXR Biosciences To Establish New Drug Screening Platform
10/19/2005 5:09:19 PM
ATLANTA--(BUSINESS WIRE)--June 22, 2005--
High Throughput In Vitro Multiple Readout Screens Expected to Reduce Development Time of New Therapies
Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, has initiated a collaboration with CXR Biosciences to establish a battery of proprietary in vitro screens to select, at an early stage, candidate molecules for further development. The underlying principle of the platform is to enable the identification of compounds with the most optimal safety or bioavailability profiles as early in the drug development process as possible. The result of this will be to advance molecules most likely to succeed into clinical development, thereby reducing the overall time-to-market of life-enhancing therapies. The screening platform will utilize predictive toxicity and drug metabolism screens to profile compounds in various cell-based and in vitro assays.
Dr Tom Shepherd, Chief Executive of CXR commented "As a significant part of the tremendous costs involved in drug development are expended on drugs that fail during the development process, not only should this platform improve the quality of candidate drugs entering the clinic, but it should also improve the cost effectiveness of the overall process. Perhaps most importantly, this platform is intended to reduce the time-to-market of critical new life-enhancing therapies."
|
|
|
|
|
|
|
|
|
|
|